Role of T regulatory suppression in autoimmunity and cancer

T 调节抑制在自身免疫和癌症中的作用

基本信息

项目摘要

In the course of evaluating the antitumor effects in mice of a cytostatic traditional Chinese Medicine, Sheng Qi Formula (studies supported by the OCCAM program of the NCI), consisting of a water extract of 2 plant roots (Radx Astragali and Panax Notoginsenga (SQF), it was noted that its antitumor effect on 4T1 breast cancer was associated with marked and consistent suppression of peripheral MDSC. SQF inhibited IL-4R, Ly6G+/Gr1+, and CD11b+ cells, as well as IL-10, IL-1arginase and H2O2 production. In combination with gemcitabine, SQF markedly reduced the growth of 4T1 breast tumor in mice. Thus, reduction in the immunosuppressive populations of MDSC promoted the antitumor effect of gemcitabine. Studies of the mechanism suggest that tumor derived G-CSF and IL-1 divert the maturation of immature DC and other immune cells toward MDSC-like functions. As MDSC infiltrate tumors, they mature into tumor-promoting alternatively activated immunosuppressive macrophages (TAM's). Means of counteracting MDSC's and TAM's are in our future plans. It has recently become clear that a subset of T cells e.g. CD4+CD25+FoxP3+T regulatory (Treg) cells are essential in the maintenance of immune homeostasis and have feedback suppressive effects on immune responses. These Treg cells have been reported to suppress autoimmune responses and consequently, unfortunately, also protect tumors from immune rejection. Our studies of Tregs have revealed that TNF by acting on the TNFR2 receptor, which is highly expressed by Tregs, unexpectantly results in their proliferative expansion and functional activation both in mice and in man. Most tumor infiltrating T cells (TIL's) actually express TNFR2 and are activated by tumor-derived TNF to be even more immunosuppressive than Tregs in peripheral lymphoid tissues. Consequently, our preliminary results show that anti-TNF reduced the growth of mouse Lewis lung and breast (4T1) tumors. Thus, by identifying better means of countering Tregs, we may be able to enhance antitumor responses to tumor vaccines.
在评估细胞抑制中药生气方(NCI OCCAM 项目支持的研究)对小鼠的抗肿瘤作用过程中,生气方由 2 种植物根(黄芪和三七 (SQF))的水提取物组成,注意到其对 4T1 乳腺癌的抗肿瘤作用与显着且持续的外周 MDSC 抑制有关。 SQF 抑制 IL-4R、Ly6G+/Gr1+ 和 CD11b+ 细胞,以及 IL-10、IL-1精氨酸酶和 H2O2 的产生。 与吉西他滨联合使用,SQF 显着减少了 4T1 乳腺肿瘤的生长 老鼠。 因此,MDSC免疫抑制群体的减少促进了吉西他滨的抗肿瘤作用。该机制的研究表明,肿瘤来源的 G-CSF 和 IL-1 将未成熟 DC 和其他免疫细胞的成熟转向 MDSC 样功能。当 MDSC 浸润肿瘤时,它们会成熟为促进肿瘤的替代激活的免疫抑制巨噬细胞 (TAM 的)。对抗 MDSC 和 TAM 的方法已在我们未来的计划中。最近已经清楚,T 细胞的一个子集,例如CD4+CD25+FoxP3+T 调节 (Treg) 细胞对于维持免疫稳态至关重要,并对免疫反应具有反馈抑制作用。据报道,这些 Treg 细胞可以抑制自身免疫反应,因此,不幸的是,它们还可以保护肿瘤免受免疫反应的影响。 拒绝。我们对 Tregs 的研究表明,TNF 通过作用于 Tregs 高度表达的 TNFR2 受体,出人意料地导致小鼠和人类的增殖扩张和功能激活。大多数肿瘤浸润 T 细胞 (TIL) 实际上表达 TNFR2,并被肿瘤源性 TNF 激活,比外周血中的 Tregs 具有更强的免疫抑制作用 淋巴组织。因此,我们的初步结果表明,抗 TNF 药物减少了小鼠 Lewis 肺和乳腺 (4T1) 肿瘤的生长。因此,通过找到更好的对抗 Tregs 的方法,我们或许能够增强对肿瘤疫苗的抗肿瘤反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOOST J OPPENHEIM其他文献

JOOST J OPPENHEIM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOOST J OPPENHEIM', 18)}}的其他基金

Studies of Receptor Interactions and Effects of Alarmins
受体相互作用和警报素作用的研究
  • 批准号:
    8937677
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Consequences of receptor cross talk on inflammation and
受体串扰对炎症和
  • 批准号:
    7338777
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Role of T regulatory suppression in autoimmunity and can
T 调节抑制在自身免疫中的作用
  • 批准号:
    7338776
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Consequences of Chemokine-Receptor Interactions: Immune
趋化因子-受体相互作用的后果:免疫
  • 批准号:
    6762184
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Role of T regulatory suppression in autoimmunity and cancer
T 调节抑制在自身免疫和癌症中的作用
  • 批准号:
    7592869
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Consequences of receptor cross talk on inflammation and algesia
受体串扰对炎症和痛觉的影响
  • 批准号:
    7592870
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Studies of Receptor Interactions and Effects of Alarmins
受体相互作用和警报素作用的研究
  • 批准号:
    10262039
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Studies of Chemokine-Receptor Interactions with Chemokines and alarmins
趋化因子受体与趋化因子和警报素相互作用的研究
  • 批准号:
    7965166
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Consequences of receptor cross talk on inflammation and algesia
受体串扰对炎症和痛觉的影响
  • 批准号:
    7965553
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:
Role of T regulatory suppression in autoimmunity and cancer
T 调节抑制在自身免疫和癌症中的作用
  • 批准号:
    8157403
  • 财政年份:
  • 资助金额:
    $ 41.26万
  • 项目类别:

相似海外基金

Autoimmune responses associated with SARS-CoV-2 infection
与 SARS-CoV-2 感染相关的自身免疫反应
  • 批准号:
    10611414
  • 财政年份:
    2022
  • 资助金额:
    $ 41.26万
  • 项目类别:
Autoimmune responses associated with SARS-CoV-2 infection
与 SARS-CoV-2 感染相关的自身免疫反应
  • 批准号:
    10373287
  • 财政年份:
    2022
  • 资助金额:
    $ 41.26万
  • 项目类别:
Regulation of allergic and autoimmune responses by ILC2-T cell interaction
ILC2-T 细胞相互作用调节过敏和自身免疫反应
  • 批准号:
    20K08766
  • 财政年份:
    2020
  • 资助金额:
    $ 41.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of Inflammasome Regulation by Autoimmune Responses and Microbial Infection in Benign Prostatic Hyperplasia
良性前列腺增生中自身免疫反应和微生物感染调节炎症小体的机制
  • 批准号:
    19K09733
  • 财政年份:
    2019
  • 资助金额:
    $ 41.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
检查点抑制剂诱导的免疫相关不良事件中循环和组织特异性自身免疫反应的识别
  • 批准号:
    10578771
  • 财政年份:
    2019
  • 资助金额:
    $ 41.26万
  • 项目类别:
Investigating autoimmune responses for tailoring biologic therapies in severe asthma
研究自身免疫反应以调整严重哮喘的生物疗法
  • 批准号:
    413281
  • 财政年份:
    2019
  • 资助金额:
    $ 41.26万
  • 项目类别:
    Salary Programs
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
检查点抑制剂诱导的免疫相关不良事件中循环和组织特异性自身免疫反应的识别
  • 批准号:
    10348146
  • 财政年份:
    2019
  • 资助金额:
    $ 41.26万
  • 项目类别:
Role of the gender biased transcription factor VGLL3 in promoting autoimmune responses in SLE
性别偏向转录因子 VGLL3 在促进 SLE 自身免疫反应中的作用
  • 批准号:
    10112808
  • 财政年份:
    2017
  • 资助金额:
    $ 41.26万
  • 项目类别:
Role of the gender biased transcription factor VGLL3 in promoting autoimmune responses in SLE
性别偏向转录因子 VGLL3 在促进 SLE 自身免疫反应中的作用
  • 批准号:
    10733674
  • 财政年份:
    2017
  • 资助金额:
    $ 41.26万
  • 项目类别:
Airway autoimmune responses and steroid insensitivity in severe eosinophilic asthma
严重嗜酸性粒细胞性哮喘的气道自身免疫反应和类固醇不敏感性
  • 批准号:
    345501
  • 财政年份:
    2016
  • 资助金额:
    $ 41.26万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了